PF-06835375
C1131003
Phase 2 mab active
Quick answer
PF-06835375 for Primary Immune Thrombocytopenia is a Phase 2 program (mab) at Pfizer with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pfizer
- Indication
- Primary Immune Thrombocytopenia
- Phase
- Phase 2
- Modality
- mab
- Status
- active